AZD6094
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Key Points Question Is savolitinib monotherapy more effective than sunitinib monotherapy on progression-free survival (PFS) in…
Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated in the tumorigenesis of human…
First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line…
Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic options. PRCC may involve…
Lung cancer is the most common cause of cancer death globally with a significant, unmet need for more efficacious treatments. The…
Purpose: Papillary renal cell carcinoma (PRCC) is the second most common cancer of the kidney and carries a poor prognosis for…
2509 Background: AZD9291 is an irreversible, mutant-selective EGFR tyrosine kinase inhibitor (TKI) developed to have potency…
487 Background: Met is a receptor tyrosine kinase that is deregulated across multiple cancer types, leading to uncontrolled tumor…
Background: Volitinib is a selective oral small molecule inhibitor of cMet kinase, which has demonstrated potent in vivo…
Aberrant receptor tyrosine kinase (RTK) signaling is a well-documented driver of disease onset and progression across myriad…